Niosomal drug delivery systems for ocular disease-recent advances and future prospects
Open accessThe DOI matches its Crossref record; 124 of the 126 references it cites were found in a registry or an index.
Abstract
The eye is a complex organ consisting of several protective barriers and particular defense mechanisms. Since this organ is exposed to various infections, genetic disorders, and visual impairments it is essential to provide necessary drugs through the appropriate delivery routes and vehicles. The topical route of administration, as the most commonly used approach, maybe inefficient due to low drug bioavailability. New generation safe, effective, and targeted drug delivery systems based on nanocarriers have the capability to circumvent limitations associated with the complex anatomy of the eye. Nanotechnology, through various nanoparticles like niosomes, liposomes, micelles, dendrimers, and different polymeric vesicles play an active role in ophthalmology and ocular drug delivery systems. Niosomes, which are nano-vesicles composed of non-ionic surfactants, are emerging nanocarriers in drug delivery applications due to their solution/storage stability and cost-effectiveness. Additionally, they are biocompatible, biodegradable, flexible in structure, and suitable for loading both hydrophobic and hydrophilic drugs. These characteristics make niosomes promising nanocarriers in the treatment of ocular diseases. Hereby, we review niosome based drug delivery approaches in ophthalmology starting with different preparation methods of niosomes, drug loading/release mechanisms, characterization techniques of niosome nanocarriers and eventually successful applications in the treatment of ocular disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Niosomes, which are comprised of uncharged single-chain surfactant and cholesterol94,95 have also shown limited success potential as non-viral gene delivery systems96–101 due to improved transfection efficiency, biocompatibility, and cellular uptake, in addition to effects on intracellular trafficking.102”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [97]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Higuchi, T. (1963) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600521210 · Cited by 4,884
Danaei, M., Dehghankhold, M., Ataei, S., Hasanzadeh Davarani, F., Javanmard, R., Dokhani, A., Khorasani, S., & Mozafari, M. R. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10020057 · Cited by 4,832 · cited 3×
“The homogeneity of the size distribution of the particles is defined by the polydispersity index (PDI) [96].”
BackgroundDiffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
The effect of particle design on cellular internalization pathways
Gratton, S. E. A., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., Napier, M. E., & DeSimone, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801763105 · Cited by 2,918 · cited 1×
“For ocular applications, particles should have narrow size distribution and small polydispersity index values as lower PDI values are better for the uptake of nanoparticles and posterior internalization [97].”
BackgroundSzoka, F., & Papahadjopoulos, D. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.9.4194 · Cited by 2,323 · cited 14×
“It has been reported that the size of SUVs are in the range of 10–100 nm, while LUVs exhibit 100–3000 nm length, and that of MLVs are greater than 5 µm.”
MethodInfluentialMüller, R. H., Radtke, M., & Wissing, S. A. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00118-7 · Cited by 2,113 · cited 1×
“Drug molecules diffuse with passive diffusion from donor unit to buffer solution in the receiver unit [42,109].”
BackgroundTherapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,080 · cited 1×
“Nanotechnology, by providing particular carriers, is advantageous in ophthalmology in providing new ways of transfer and release, extending the drug efficacy and enabling intracellular delivery [4,5].”
BackgroundNon-ionic surfactant based vesicles (niosomes) in drug delivery
Uchegbu, I. F., & Vyas, S. P. (1998) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(98)00169-0 · Cited by 1,020 · cited 1×
“Furthermore, the capability of niosomes in enhancing the bioavailability and efficacy of drugs attracts the researchers’ attention to apply niosomal drug delivery systems in treatment of severe inflammations and diseases such as different types of cancers [15,16].”
BackgroundChallenges and obstacles of ocular pharmacokinetics and drug delivery
Urtti, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.027 · Cited by 1,003 · cited 1×
“Topical eye drops are the most prevalent way of ocular therapy for the anterior part of the eye, which includes the conjunctiva, cornea, sclera, and anterior uvea [1].”
BackgroundNano-niosomes as nanoscale drug delivery systems: An illustrated review
Moghassemi, S., & Hadjizadeh, A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.015 · Cited by 797 · cited 1×
“Because of the pH difference inside (lower pH) and outside (higher pH) of the niosome, the ionized drug cannot go out and is trapped inside of the vesicle [39,87].”
Background
Research works printed but not linked: 3
- More V.V. Gilhotra R.M. Nitalikar M.M. Khule P.K. Niosomal Drug Delivery-A Comprehensive Review Asian J. Pharm. 2019 12 S1159 S1164
- Lakshmi P.K. Bhaskaran S. Phase II study of topical niosomal urea gel-an adjuvant in the treatment of psoriasis Int. J. Pharm. Sci. Rev. Res. 2011 7 1 7
- Biswas G.R. Majee S.B. Niosomes in ocular drug delivery Eur. J. Pharm. Med. Res. 2017 4 813 819
Cited by
Alkilani, A. Z., Nasereddin, J., Hamed, R., Nimrawi, S., Hussein, G., Abo-Zour, H., & Donnelly, R. F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061152 · Cited by 201
Current advances in niosomes applications for drug delivery and cancer treatment
Moammeri, A., Chegeni, M. M., Sahrayi, H., Ghafelehbashi, R., Memarzadeh, F., Mansouri, A., Akbarzadeh, I., Abtahi, M. S., Hejabi, F., & Ren, Q. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100837 · Cited by 195
Hyaluronic acid in ocular drug delivery
Zhang, X., Wei, D., Xu, Y., & Zhu, Q. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118006 · Cited by 196
Synthesis and Potential Applications of Lipid Nanoparticles in Medicine
Musielak, E., Feliczak-Guzik, A., & Nowak, I. (2022) · Materials · doi:10.3390/ma15020682 · Cited by 159
“Due to their non-ionic nature, they provide high biocompatibility and low toxicity [33].”
BackgroundMethodInfluentialNanomaterials as Nanofertilizers and Nanopesticides: An Overview
Okey‐Onyesolu, C. F., Hassanisaadi, M., Bilal, M., Barani, M., Rahdar, A., Iqbal, J., & Kyzas, G. Z. (2021) · ChemistrySelect · doi:10.1002/slct.202102379 · Cited by 179
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Cellulosic Polymers for Enhancing Drug Bioavailability in Ocular Drug Delivery Systems
Gupta, B., Mishra, V., Gharat, S., Momin, M. M., & Omri, A. (2021) · Pharmaceuticals · doi:10.3390/ph14111201 · Cited by 156
“The topical route is preferred for management of anterior segment diseases, due to their low cost, ease of administration, and patient compliance [19,20].”
BackgroundThymoquinone, as a Novel Therapeutic Candidate of Cancers
Almajali, B., Al‐Jamal, H. A. N., Taib, W. R. W., Ismail, I., Johan, M. F., Doolaanea, A. A., & Ibrahim, W. N. (2021) · Pharmaceuticals · doi:10.3390/ph14040369 · Cited by 119
“from the self-assembly of nonionic surfactants, resulting in closed bilayer structures [47].”
BackgroundLipid-Based Nanoformulations for Drug Delivery: An Ongoing Perspective
Rehman, M., Tahir, N., Sohail, M. F., Qadri, M. U., Duarte, S. O. D., Brandão, P., Esteves, T., Javed, I., & Fonte, P. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111376 · Cited by 132
Magnetic Nanoparticles and Drug Delivery Systems for Anti-Cancer Applications: A Review
Graham, W., Torbett-Dougherty, M., Islam, A. B., Soleimani, S., Bruce‐Tagoe, T. A., & Johnson, J. A. (2025) · Nanomaterials · doi:10.3390/nano15040285 · Cited by 111
“Niosomes (Figure 17C) are stable and cheaper carrier matrices and have structures similar to liposomes, except that the vesicle is made from non-ionic surfactants [110,111].”
Alkilani, A. Z., Hamed, R., Abdo, H., Swellmeen, L., Basheer, H. A., Wahdan, W., & Kwiak, A. D. A. (2022) · ACS Omega · doi:10.1021/acsomega.2c03762 · Cited by 74
Niosomes: A Novel Carrier Drug Delivery System
ARUMUGAM, K., BORAWAKE, P. D., Shinde, J. V., & Chavan, R. S. (2021) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v11i1.4479 · Cited by 67
“It has been reported that the size of the small unilamellar vesicles are in the range of 10-100 nm [38, 39].”
BackgroundRecent developments and applications of smart nanoparticles in biomedicine
Campora, S., & Ghersi, G. (2022) · Nanotechnology Reviews · doi:10.1515/ntrev-2022-0148 · Cited by 86
Exploring Protein-Based Carriers in Drug Delivery: A Review
Ferraro, C., Dattilo, M., Patitucci, F., Prete, S., Scopelliti, G., Parisi, O. I., & Puoci, F. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091172 · Cited by 70
“Since then, niosomes have been widely studied for various applications across different fields, including pharma-ceuticals and food sciences [53,54].”
BackgroundKhan, M. S., Mohapatra, S., Gupta, V., Ali, A., Naseef, P. P., Kuruniyan, M. S., Alshadidi, A. A. F., Alam, M. S., Mirza, M. A., & Iqbal, Z. (2023) · Membranes · doi:10.3390/membranes13030343 · Cited by 66
Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa
Tang, J., Cai, L., Xu, C., Sun, S., Liu, Y., Rosenecker, J., & Guan, S. (2022) · Nanomaterials · doi:10.3390/nano12020226 · Cited by 63
El-Far, S. W., El-Enin, H. A. A., Abdou, E. M., Nafea, O. E., & Abdelmonem, R. (2022) · Pharmaceuticals · doi:10.3390/ph15070816 · Cited by 59
“Drug-free niosomes were prepared by a thin film hydration method [20,77].”
MethodOptimization of curcumin loaded niosomes for drug delivery applications
Rad, M. E., Egil, A. C., İnce, G. Ö., Yüce, M., & Zarrabi, A. (2022) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2022.129921 · Cited by 54
Self-citationJoy, R., George, J., & John, F. (2022) · ChemistrySelect · doi:10.1002/slct.202104045 · Cited by 50
Roostaee, M., Derakhshani, A., Mirhosseini, H., Mofakham, E. B., Fathi‐karkan, S., Mirinejad, S., Sargazi, S., & Barani, M. (2023) · Nanoscale · doi:10.1039/d3nr03495j · Cited by 54
Wang, Y., & Wang, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061150 · Cited by 59
Narayana, S., Ahmed, M. G., Gowda, B. H. J., Shetty, P., Nasrine, A., Thriveni, M., Noushida, N., & Sanjana, A. (2021) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-021-00331-2 · Cited by 49
Jayoush, A. R. A., Hassan, H. A. F. M., Asiri, H., Jafar, M., Saeed, R., Harati, R., & Haider, M. A. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105007 · Cited by 55
Alkilani, A. Z., Abu-Zour, H., Alshishani, A., Abu‐Huwaij, R., Basheer, H. A., & Abo-Zour, H. (2022) · Nanomaterials · doi:10.3390/nano12203570 · Cited by 42
“Vesicle size, surfactant type, and Chol concentration are the factors affecting the effectiveness of entrapment [34].”
BackgroundTopical drug delivery to the retina: obstacles and routes to success
Loftsson, Þ. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2017878 · Cited by 44
Niosome as an Effective Nanoscale Solution for the Treatment of Microbial Infections
Barani, M., Paknia, F., Roostaee, M., Kavyani, B., Kalantar-Neyestanaki, D., Ajalli, N., & Amirbeigi, A. (2023) · BioMed Research International · doi:10.1155/2023/9933283 · Cited by 49
“Accordingly, niosomes are classified into three groups based on the number of bilayers or their size: small unilamellar vesicles (SUVs, 10-100 nm), large unilamellar vesicles (LUVs, 1003000 nm), and multilamellar vesicles (MLVs, >5μm) [18, 79, 80] (Figure 1).”
BackgroundFunctional Evaluation of Niosomes Utilizing Surfactants in Nanomedicine Applications
Gao, S., Sui, Z., Jiang, Q., & Jiang, Y. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s480639 · Cited by 52
Piri-Gharaghie, T., Shirin, N. J., Saremi-Nouri, S., Khademhosseini, S.-H., Hoseinnezhad-lazarjani, E., Mousavi, A., Kabiri, H., Rajaei, N., Riahi, A., Biregani, A. F., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09195-9 · Cited by 41
Nanomedicines for the treatment of glaucoma: Current status and future perspectives
Zhai, Z., Cheng, Y., & Hong, J. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.02.017 · Cited by 42
Sakr, M. G., El‐Zahaby, S. A., Al-mahallawi, A. M., & Ghorab, D. M. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104363 · Cited by 39
Gawin-Mikołajewicz, A., Nawrot, U., Malec, K., Krajewska, K., Nartowski, K. P., & Karolewicz, B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010011 · Cited by 38
“This makes the final formulation with niosomes less stable and requires parameter control at all steps, resulting in a time-consuming technology process [26,28,29].”
The Emerging Role of Topical Ocular Drugs to Target the Posterior Eye
Wang, L., Zhou, M., & Zhang, H. (2021) · Ophthalmology and Therapy · doi:10.1007/s40123-021-00365-y · Cited by 43
Bourbour, M., Khayam, N., Noorbazargan, H., Yaraki, M. T., Lalami, Z. A., Akbarzadeh, I., Yeganeh, F. E., Dolatabadi, A., rad, F. M., & Tan, Y. N. (2022) · Molecular Systems Design & Engineering · doi:10.1039/d2me00024e · Cited by 37
Kattar, A., Quelle‐Regaldie, A., Sanchez, L. E., Concheiro, Á., & Alvarez‐Lorenzo, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041247 · Cited by 36
“The shape, size, and surface charge can be modified by adjusting the concentration and molar ratios of different reagents [23,24].”
BackgroundMaterial and Design Toolkit for Drug Delivery: State of the Art, Trends, and Challenges
Rad, M. E., Soylukan, C., Kulabhusan, P. K., Günaydın, B. N., & Yüce, M. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c10065 · Cited by 37
Niosomal Bupropion: Exploring Therapeutic Frontiers through Behavioral Profiling
Harini, K., Alomar, S. Y., Mohammed, V., Manoharadas, S., Thirumalai, A., Girigoswami, K., & Girigoswami, A. (2024) · Pharmaceuticals · doi:10.3390/ph17030366 · Cited by 40
Topical Ocular Drug Delivery: The Impact of Permeation Enhancers
Santos, G., Delgado, E., Silva, B., Bráz, B. S., & Gonçalves, L. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17040447 · Cited by 42
Pirojiya, H., & Dudhat, K. R. (2024) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-024-00373-x · Cited by 44
“Niosomes are an effective tool in both established and developing healthcare systems because of their cost-effectiveness [11, 16]. have been the subject of much research worldwide for the past 20 years due to their potential to increase medication stability, improve bioavailability, and enable…”
Abtahi, N. A., Naghib, S. M., Haghiralsadat, F., Reza, J. Z., Hakimian, F., Yazdian, F. A., & Tofighi, D. (2021) · Nanotechnology Reviews · doi:10.1515/ntrev-2021-0119 · Cited by 31
Niosomes as Vesicular Nanocarriers in Cosmetics: Characterisation, Development and Efficacy
Lens, M. B. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030287 · Cited by 36
“To create niosome vesicles, samples are combined and heated while being stirred (800–1000 rpm) for 30 min in a nitrogen environment [55].”
Drug delivery strategies to improve the treatment of corneal disorders
Tafti, M. F., Fayyaz, Z., Aghamollaei, H., Jadidi, K., & Faghihi, S. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41881 · Cited by 32
Polyacrylic Acid: A Biocompatible and Biodegradable Polymer for Controlled Drug Delivery
Eslami, H., Ansari, M., Darvishi, A., Pisheh, H. R., Shami, M., & Kazemi, F. (2023) · Polymer Science Series A · doi:10.1134/s0965545x2460011x · Cited by 26
Mirgorodskaya, A. B., Koroleva, M. Y., Kushnazarova, R. A., Mishchenko, E. V., Petrov, K. A., Lenina, O. A., Vyshtakalyuk, A. B., Voloshina, A. D., & Zakharova, L. Y. (2021) · Nanotechnology · doi:10.1088/1361-6528/ac467d · Cited by 25
Food-based Polymers for Encapsulation and Delivery of Bioactive Compounds
Ekrami, M., Ekrami, A., Moghaddam, R. H., Ahranjani, P. J., & Emam‐Djomeh, Z. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839168048-00488 · Cited by 30
Recent Developments in Gene Therapy for Neovascular Age-Related Macular Degeneration: A Review
Finocchio, L., Zeppieri, M., Gabai, A., Toneatto, G., Spadea, L., & Salati, C. (2023) · Biomedicines · doi:10.3390/biomedicines11123221 · Cited by 34
Application of Silicone in Ophthalmology: A Review
Mladenović, T., Živić, F., Petrovic, N. T., Nježić, S., Pavić, J., Kotorčević, N., Milenković, S., & Grujović, N. (2024) · Materials · doi:10.3390/ma17143454 · Cited by 32
“For example, emerging nanotechnologies promise to contribute to more efficient solutions [121–125] and especially to drug delivery systems [33,126,127].”
BackgroundNiosome-based hydrogel as a potential drug delivery system for topical and transdermal applications
Nigro, F., Pinto, C. D. S. C., dos Santos, E. P., & Mansur, C. R. E. (2020) · International Journal of Polymeric Materials · doi:10.1080/00914037.2020.1848833 · Cited by 28
“For topical ocular treatments, nanotechnology is also applied for providing a new strategy of encapsulated drug delivery to the different eye locations, especially to the posterior portion, replacing uncomfortable injections([34]).”
Mawazi, S. M., Ann, T. J., & Widodo, R. T. (2024) · BioNanoScience · doi:10.1007/s12668-024-01395-z · Cited by 24
“Size reduction must be subjected to the already created LUVs in order to obtain small unilamellar vesicles [8–10, 23, 48].”
InfluentialTargeted Lipid-Based Drug Delivery Systems for Lung Cancer Therapy
Apostolou, M., Fatokun, A. A., Assi, S. A., & Khan, I. (2024) · Applied Sciences · doi:10.3390/app14156759 · Cited by 24
“Other routes of administration for niosomes include transdermal [71], oral [72] and ocular [73].”
Bidaki, A., Rezaei, N., Kazemi, S., Ali, S. N., Ziaei, S., Moeinzadeh, A., Hosseini, F., Noorbazargan, H., Farmani, A. R., & Ren, Q. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143743 · Cited by 26
Hair surface engineering: Combining nanoarchitectonics with hair topical and beauty formulations
Guryanov, I., Naumenko, E., & Fakhrullin, R. F. (2021) · Applied Surface Science Advances · doi:10.1016/j.apsadv.2021.100188 · Cited by 24
Abou‐Taleb, H. A., Sayed, A. M., Refaat, H., Alsenani, F., Alaaeldin, E., Mokhtar, F. A., Abdelmohsen, U. R., & Shady, N. H. (2022) · Marine Drugs · doi:10.3390/md20100628 · Cited by 24
“They are more advantageous than other nanocarriers, such as liposomes, because they are more stable and cost-effective [13].”
BackgroundAkbarzadeh, I., Rezaei, N., Bazzazan, S., Mezajin, M. N., Mansouri, A., Karbalaeiheidar, H., Ashkezari, S., Moghaddam, Z. S., Lalami, Z. A., & Mostafavi, E. (2023) · Biomaterials Advances · doi:10.1016/j.bioadv.2023.213384 · Cited by 23
Saharkhiz, S., Zarepour, A., & Zarrabi, A. (2023) · Bioengineering · doi:10.3390/bioengineering10101159 · Cited by 28
“They deliver therapeutic compounds to the intended site and reduce the side effects on normal tissues and cells [11].”
BackgroundSelf-citationSiafaka, P. I., Bülbül, E. Ö., Miliotou, Α. N., Karantas, I. D., Okur, M. E., & Okur, N. Ü. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105381 · Cited by 31
Beram, F. M., Ali, S. N., Mesbahian, G., Pashizeh, F., Keshvadi, M., Mashayekhi, F., Khodadadi, B., Bashiri, Z., Moeinzadeh, A., Rezaei, N., et al. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00814 · Cited by 24
RetractedPaseban, K., Noroozi, S., Gharehcheloo, R., Haddadian, A., Robattorki, F. F., Dibah, H., Amani, R., Sabouri, F., Ghanbarzadeh, E., Hajrasouiha, S., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35651 · Cited by 22
“Recent studies have focused on the use of niosome as drug delivery systems for anti-microbial agents [23].”
BackgroundMethodInfluentialRaoufi, E., Bahramimeimandi, B., Salehi‐Shadkami, M., Chaosri, P., & Mozafari, M. R. (2021) · Biomedicines · doi:10.3390/biomedicines9050520 · Cited by 25
“Moreover, their characteristics such as biocompatibility, biodegradability, and flexibility in structure have made them ideal carriers for loading hydrophobic and hydrophilic drugs [71].”
BackgroundZenjanab, M. K., Pakchin, P. S., Fathi, M., Abdolahinia, E. D., & Adibkia, K. (2024) · Biomedical Materials · doi:10.1088/1748-605x/ad2ed5 · Cited by 21
“They are also flexible in structure, biocompatible, and suitable for loading both hydrophobic and hydrophilic drugs [13].”
The effects of aging on the mechanical properties of the vitreous
Levin, M., & Cohen, N. (2021) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2021.110310 · Cited by 22
Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye
Popova, E. V., Tikhomirova, V. E., Валерьевна, Б. О., Chesnokova, N. B., Grigoriev, Y. V., Klyachko, N. L., & Kost, O. A. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102493 · Cited by 19
Nasr, A. M., Elhady, S. S., Swidan, S. A., & Badawi, N. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121157 · Cited by 21
“Vesicular systems such as liposomes and niosomes are the most common carriers used in order to entrap the drug molecules [9].”
BackgroundGu, D., Pan, H., Xu, S., Chen, W., Zhu, R., Jiang, W., & Pan, W. (2022) · AAPS PharmSciTech · doi:10.1208/s12249-022-02418-2 · Cited by 19
A Comprehensive Review on Niosomes in Drug Delivery and Recent Advancements
Teron, C., Bhuyan, A., Saikia, P., Dutta, S. R., Gogoi, H., & Rongpi, S. (2024) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v14i6.6651 · Cited by 29
Alkilani, A. Z., Sharaire, Z., Hamed, R., & Basheer, H. A. (2024) · ACS Omega · doi:10.1021/acsomega.4c01224 · Cited by 26
Kalam, M. A., Iqbal, M., Alshememry, A. K., Alkholief, M. A., & Alshamsan, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071328 · Cited by 18
“, liposomes) [2,15–17], nanocrystals by top-down or bottom-up techniques [5,7,9,15,18], polymeric micelles [19], polymeric nanoparticles (NPs) [3,20], nanoemulsion [1,21], microemulsion [22], solid lipid nanoparticles [10,23,24], niosomes [25,26], dendrimer nanoparticles [27,28] etc.”
BackgroundAdvanced Drug Delivery Systems
Prajapati, B. G. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100967 · Cited by 19
Baldino, L., & Reverchon, E. (2022) · The Journal of Supercritical Fluids · doi:10.1016/j.supflu.2022.105673 · Cited by 17
Liu, X., Guo, F., Liang, D., Li, Z., Cao, Y., Chen, M., Xu, J., Liu, X., & Zhong, H. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104725 · Cited by 17
RNA nanotechnology: A new chapter in targeted therapy
Lv, T., Meng, Y., Liu, Y., Han, Y., Xin, H., Peng, X., & Huang, J. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113533 · Cited by 20
Exploring the use of niosomes in cosmetics for efficient dermal drug delivery
Abu‐Huwaij, R., Alkarawi, A., Salman, D., & Alkarawi, F. (2023) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2023.2233613 · Cited by 18
Hajinezhad, M. R., Roostaee, M., Nikfarjam, Z., Rastegar, S., Sargazi, G., Barani, M., & Sargazi, S. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03099-3 · Cited by 16
“Notably, they possess excellent encapsulation capabilities, are biocompatible, exhibit reduced toxicity, biodegrade naturally, and can be prepared at a low cost (Durak et al. 2020).”
Wen, S., Qin, C., Shen, L., Liu, D., Zhu, S., & Lin, Q. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c01557 · Cited by 16
Enhancement of the Anti-inflammatory Efficacy of Betamethasone Valerate via Niosomal Encapsulation
(2021) · Biointerface Research in Applied Chemistry · doi:10.33263/briac116.1464014660 · Cited by 22
“PDI was determined as a measure of homogeneity [24] and was expressed as following [25]: Standard deviation Mean droplet size”
Aldawsari, M. F., Moglad, E. H. O., Alotaibi, H. F., Alkahtani, H. M., & Khafagy, E. (2023) · Polymers · doi:10.3390/polym15214336 · Cited by 20
Alotaibi, T. A., Iyire, A., Assaf, S. M., & Dahmash, E. Z. (2024) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-024-00598-1 · Cited by 18
“Niosomes are made of a surfactant bilayer with the hydrophilic heads found on the surface, and inside, of the vesicle while the hydrophobic tails form the bilayer; this allows for two different areas for drug entrapment [12].”
BackgroundAzrak, Z. A. T., Taha, M. S., Jagal, J., Elsherbeny, A., Bayraktutan, H., AbouGhaly, M. H. H., Elshafeey, A. H., Greish, K. F., & Haider, M. A. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.123935 · Cited by 15
Kattar, A., Concheiro, Á., & Alvarez‐Lorenzo, C. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1953466 · Cited by 16
Polysaccharides polymers for glaucoma treatment-a review
Ahmed, T., Islam, M. N., Monalisa, R., Ehsan, F., & Huang, S.-W. (2023) · European Journal of Ophthalmology · doi:10.1177/11206721231178057 · Cited by 14
“61 Niosomes are superior to gelling systems because of higher chemical stability of surfactants.”
BackgroundAqueous Prostaglandin Eye Drop Formulations
Jansook, P., & Loftsson, Þ. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102142 · Cited by 13
“Niosomes are promising ocular delivery systems formed by the self-assembly of nonionic surfactants in aqueous solutions [65,66].”
BackgroundAbdulkareem, S. J., Jafari-Gharabaghlou, D., Jadid, M. F. S., Salmani-Javan, E., Toroghi, F., & Zarghami, N. (2024) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-023-00495-7 · Cited by 16
“The loading efficiency of hydrophilic drugs may be influenced by the larger aqueous internal volume of niosomes [74].”
Engineered Niosomes for Cancer Therapy: Classification, Synthesis, and Clinical Applications
Hashemi, Z., Beheshtizadeh, N., Jaymand, M., Jahanban‐Esfahlan, A., Akbari, M., & Jahanban‐Esfahlan, R. (2024) · BioNanoScience · doi:10.1007/s12668-024-01647-y · Cited by 16
“…solvent-free, high EE%, suitable for protein encapsulation Risk of drug leakage, potential vesicle fusion, larger vesicles with high PDI [33, 70, 71] Transmembrane pH gradient method High EE% for amphiphilic and acidic drugs, active drug loading, low cost Difficult to standardize and reproduce,…”
Yassin, G. E., Amer, M. A., Mannaa, I. M., & Khalifa, M. K. A. (2024) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-024-09850-w · Cited by 12
“…vesicular drug delivery systems (phospho - lipid vesicles as liposomes and non-ionic surfactant vesi - cles as niosomes) have been employed in ophthalmology to achieve prolonged drug release and reduce enzymatic drug metabolism at the ocular surface and at the corneal surface, respectively [19].”
Drug Encapsulation: Review of Niosomes for Promoting Antimicrobial Activity
do Nascimento, T., Garófalo, D. D. A., Monteiro, M. S. D. S. D. B., Santos‐Oliveira, R., Matos, A. P. D. S., & Ricci‐Júnior, E. (2022) · Journal of Nanoparticle Research · doi:10.1007/s11051-022-05637-7 · Cited by 12
“In the case of niosomes, with this methodology, it is possible to evaluate whether the vesicles are multilamellar or unilamellar, which also influences drug release and the behavior of these systems in the body [11, 72, 73].”
BackgroundMethodKianinejad, N., Razeghifard, R., Omidian, H., Omidi, Y., & Kwon, Y. M. (2024) · Journal of Liposome Research · doi:10.1080/08982104.2024.2410748 · Cited by 14
“With nio-somes having demonstrated effectiveness as drug carriers in numerous clinical trials, the current focus is on obtaining the necessary approvals for their use in drug delivery [14–16].”
Popova, E. V., Matveeva, O., Валерьевна, Б. О., Tikhomirova, V. E., Kudryashova, E. V., Grigoriev, Y. V., Chesnokova, N. B., & Kost, O. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020550 · Cited by 10
Alshememry, A. K., Alkholief, M. A., Kalam, M. A., Raish, M., Ali, R., Alhudaithi, S. S., Iqbal, M., & Alshamsan, A. (2022) · Molecules · doi:10.3390/molecules27144619 · Cited by 10
“The NCs were prepared using asmall amount of stabilizer(s) with a drug [6–8], representing a good alternative to the existing colloidal nanocarriers such asnanoemulsions [9,10], microemulsion [11,12], liposomes [13,14], niosomes [15,16], polymeric nanoparticles (NPs) [17,18], dendrimer nanoparticles [19,20], solid lip…”
MethodAn overview of ocular drug delivery systems—conventional and novel drug delivery systems
Virmani, T., Kumar, G., Sharma, A., & Pathak, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15264-1.00007-5 · Cited by 13
Recent advances in the formulation strategy to improve iron bioavailability: A review
Rout, S. R., Pradhan, D., Haldar, J., Rajwar, T. K., Dash, P., Dash, C., Kumar, V., Kar, B., Ghosh, G., & Rath, G. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105633 · Cited by 11
Badran, M. M., Alsubaie, A., Salem-Bekhit, M. M., Alomrani, A. H., Almomen, A. A., Ibrahim, M. A., & Alshora, D. H. (2024) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2024.102208 · Cited by 14
“The long alkyl chain, a gel transition temperature of 56 to 58 ◦ C, and an HLB value of 4.7 of span 60 can raise the EE% for many drugs (Durak et al., 2020).”
InfluentialChaudhari, P., Lewis, S. A., & Ghate, V. (2025) · Contact Lens and Anterior Eye · doi:10.1016/j.clae.2025.102367 · Cited by 11
Mubarak, N., Waqar, M. A., Khan, A. M., Asif, Z., Alvi, A. S., Virk, A. A., & Amir, S. (2025) · Designed Monomers & Polymers · doi:10.1080/15685551.2025.2464132 · Cited by 12
Enhanced anticancer efficacy of oxaliplatin-loaded PEGylated niosomes in breast cancer treatment
Moghaddam, N. A., Mohammadgholi, A., Mojtahedi, F., Akhtari, N., Farsani, N. K., & Noorbazargan, H. (2025) · Cancer Nanotechnology · doi:10.1186/s12645-025-00309-2 · Cited by 9
“Like this, an ideal Tween 60:Span 60 ratio reduces particle size by preserving a balanced hydrophilic–lipo-philic profile, whereas larger and less stable particles are the consequence of surfactant composition imbalances (Durak et al. 2020).”
Plant-Derived Exosome-Coated Niosome Oxygen Nanobubbles for the Mitigation of Ocular Ischemia
Bushra, A., Fall, M., Ren, W., Igbalaye, J. O., & Irudayaraj, J. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00363 · Cited by 9
Sultana, S., Yusuf, M., & Sharma, V. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03159-8 · Cited by 12
“The sustained release capability of niosomes may significantly improve patient outcomes by preventing long-term complications associated with corneal dystrophies such as impaired vision [320, 321].”
Al-Ali, M., & Al-Ali, L. I. (2024) · Tikrit Journal of Engineering Sciences · doi:10.25130/tjes.31.4.8 · Cited by 10
Non-Viral Delivery Systems to Transport Nucleic Acids for Inherited Retinal Disorders
Jony, M. J. H., Joshi, A., Dash, A. K., & Shukla, S. (2025) · Pharmaceuticals · doi:10.3390/ph18010087 · Cited by 12
Current state and potential of polymersomes as ocular drug delivery systems
Yetisgin, A. A., Sivakumar, P. M., & Çetinel, S. (2025) · Nanoscale · doi:10.1039/d5nr01273b · Cited by 12
Application of nanotechnology in anti-aging cosmetics: advantages, challenges, and prospects
Pan, X., Zhong, Z., Hu, X., Wu, J., Huang, W., Li, W., Zhao, Y., Xie, Y., Huang, Y., Liang, J., et al. (2025) · Polymer Bulletin · doi:10.1007/s00289-025-05903-3 · Cited by 16
Elegant, Flexible Vesicular Nanocarriers for the Efficient Skin Delivery of Topically Applied Drugs
Albalawi, W. I., Alharbi, S., Alanazi, F., Alahmadi, H., Alghamdi, M., Soliman, G. M., & Safwat, M. A. (2021) · Current Nanoscience · doi:10.2174/1573413718666211230111538 · Cited by 9
Metadata
- Authors
- Durak, S., Esmaeili Rad, M., Alp Yetisgin, A., Eda Sutova, H., Kutlu, O., Cetinel, S., & Zarrabi, A.
- Affiliations
- Sabancı Üniversitesi (TR)
- Nanotechnology Research and Application Center (SUNUM), Sabanci University, Istanbul 34956, Turkey
- Corresponding author
- Zarrabi, Ali
- Venue
- Nanomaterials
- Publisher
- MDPI AG
- Published
- 2020-06-18
- Volume
- 10
- Issue
- 6
- Pages
- 1191
- ISSN
- 2079-4991 (ISSN-L)
- PMC
- PMC7353242
- OpenAlex
- W3036547471
- Cited by
- 196
- References
- 126
- Citations by year
- 2026: 26 · 2025: 35 · 2024: 44 · 2023: 40 · 2022: 27 · 2021: 22 · 2020: 2
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Nanomaterials (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Sabanci University (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- SUNUM (I.A.SN-19-00005 (S.C.) and I.A.SN-19-00001 (A.Z.))
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- niosomes, ocular drug delivery, nonionic surfactants, nanocarriers, eye diseases, drug loading and release, niosome characterization, topical ocular administration, drug bioavailability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.